Paul Haluska Jr., M.D., Ph.D.
Long-Term Research Interests:
Mid-Term Research Interests:
My research interests focus on using in vitro and in vivo lab-based models to understand the mechanism of resistance to anti-cancer therapies and devise strategies to overcome this resistance. My lab has focused on targeting the insulin-like growth factor 1 receptor (IGF-1R) in breast and ovarian cancer models. The IGF-1R in these, and other cancers, provides prosurvival and proliferative signaling. Mounting evidence supports signaling through the IGF-1R as a mechanism of resistance to commonly used anti-cancer therapies, such as cytotoxic chemotherapy, hormonal therapies, trastuzumab and radiation. My lab has been focusing on combining agents targeting the IGF-1R with many of these therapies with the goal of translating these findings into clinical trials. For instance, through our work identifying crosstalk between the IGF-1R and HER2, we provided the preclinical rationale for N0733, a Phase II study of capecitabine + lapatinib +/- the anti-IGF-1R monoclonal antibody, IMC-A12 in HER2 + breast cancer patients.
M.D., Ph.D. Program
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.